Cafepharma Daily Premium (On-Demand) Archive for March, 2019

Click a link below to view the mailing archive as if it had been sent to you.

2019-03-31 17:56		CP Sun Premium: Merck KGaA finally gets their MS drug approval
2019-03-31 00:08		CP Sat Premium: Antibiotic innovation
2019-03-30 00:13		CP Fri Evening Premium: Takeda steps into gene therapy with StrideBio
2019-03-29 13:37		CP Fri Premium: Bristol-Myers bets on AI for oncology RWD
2019-03-28 23:41		CP Thu Evening Premium: Gilead's RA trial win
2019-03-28 13:09		CP Thu Premium: So much AstraZeneca news
2019-03-27 23:51		CP Wed Evening Premium: Outcomes-based drug pricing
2019-03-27 12:50		CP Wed Premium: March Madness for life science IPOs
2019-03-27 00:08		CP Tue Evening Premium: Biotech unicorn Sana Bio
2019-03-26 13:21		CP Tue Premium: DOJ supports Trump's ruling to strike down ACA, including biosimilar provisions
2019-03-25 22:40		CP Mon Evening Premium: Troubled Allergan is taking steps to appease investors
2019-03-25 17:36		CP Premium: SPECIAL NOTICE about upcoming changes to your newsletter
2019-03-25 13:58		CP Mon Premium: Aimmune advancing peanut allergy treatment in EU and US
2019-03-24 20:45		CP Sun Premium: Upcoming blockbuster drug launches
2019-03-23 15:00		CP Sat Premium: Who should Biogen buy?
2019-03-22 22:27		CP Fri Evening Premium:Is AI and medicine hyped?
2019-03-22 12:15		CP Fri Premium: Biogen not leaving amyloid beta theory behind yet
2019-03-21 23:19		CP Thu Evening Premium: Imago raises $40M
2019-03-21 13:09		CP Thu Premium: Biogen halts Alzheimers trials
2019-03-21 00:20		CP Wed Evening Premium: How Exact Sciences turned around
2019-03-20 14:33		CP Wed Premium: Does GSK have competition for Keytruda in endometrial cancer?
2019-03-19 23:44		CP Tue Evening Premium: Sage's PPD drug approved + gene therapy buyouts
2019-03-19 12:44		CP Tue Premium: New indication for Roche's Tecentiq
2019-03-18 23:55		CP Mon Evening Premium: Women biotech pioneers
2019-03-18 13:05		CP Mon Premium: Abbott, Amarin, and AZ news from cardiology meeting
2019-03-17 20:14		CP Sun Premium: Diabetes companies to watch + first day ACC conference
2019-03-16 13:27		CP Sat Premium: Non-opioid painkiller space heats up
2019-03-16 00:03		CP Fri Evening Premium: Latest on Celgene -- BMS
2019-03-15 12:41		CP Fri Premium: Keytruda's blockbuster potential in China
2019-03-15 00:07		CP Thu Evening Premium: What's known about Haven
2019-03-14 12:37		CP Thu Premium: NYC getting hotter for life science startups?
2019-03-14 00:05		CP Wed Evening Premium: Industry insiders like FDA chair pick
2019-03-13 14:25		CP Wed Premium: AbbVie's Humira has top Rx spot again for 2018
2019-03-12 23:23		CP Tue Evening Premium: New acting FDA chair + GeNeuro MS trial
2019-03-12 12:48		CP Tue Premium: Survey of biotech execs predicts big M&A deals for 2019
2019-03-11 22:44		CP Mon Evening Premium: Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
2019-03-11 12:52		CP Mon Premium: How pharmas, PBMs and payers affect drug price through the supply chain
2019-03-10 21:19		CP Sun Premium: Private medtech companies to watch
2019-03-09 14:16		CP Sat Premium: AI diagnostics for cancer and type 1 diabetes
2019-03-08 23:38		CP Fri Evening Premium: FDA panel doesn't back Sanofi dengue vaccine
2019-03-08 12:53		CP Fri Premium: Gilead shares early clinical data on HIV capsid inhibitor
2019-03-07 21:57		CP Thu Evening Premium: Spark bidding war drove Roche bid up by $2.1 billion
2019-03-07 13:52		CP Thu Premium: Shkreli may be running a pharma company from prison
2019-03-06 23:03		CP Wed Evening Premium: Allergan antidepressant fails trials
2019-03-06 13:34		CP Wed Premium: What will be Gottlieb's legacy?
2019-03-06 00:47		CP Tue Evening Premium: Gottlieb resigns; esketamine drug approved
2019-03-05 13:52		CP Tue Premium: Allergan activists want Saunders gone
2019-03-04 23:55		CP Mon Evening Premium: Orkambi UK price standoff
2019-03-04 12:28		CP Mon Premium: Biogen buying ophthalmology gene therapy company
2019-03-03 22:56		CP Sun Premium: The latest CHMP recommendations
2019-03-03 22:51		CP Sat Premium:A closer look at the drug rebate proposal
2019-03-02 13:04		CP Sat Premium:A closer look at the drug rebate proposal
2019-03-02 00:09		CP Fri Evening Premium: New type of Herceptin approved
2019-03-01 12:47		CP Fri Premium: Pfizer's Xeljanz safety an issue in Europe too

<< Archive Index • Subscribe >>

Cafepharma Daily Premium (On-Demand) Archive for March, 2019

Contact Us

Past Issues

Unsubscribe